Birk POLLER (Novartis)   SITE

  • Drug Metab Dispos. 2021;49:389-394. Clinical investigation of metabolic and renal clearance pathways contributing to the elimination of Fevipiprant using Probenecid as perpetrator. Weiss HM, Langenickel T, Cain M, Kulkarni S, Shah B, Vemula J, Rahmanzadeh G, Poller B. PubMed
  • Pulm Pharmacol Ther. 2019;57:101809. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Poller B, Woessner R, Barve A, Tillmann HC, Vemula J, Nica A, Elbast W, Schiller H, End P, Camenisch G, Weiss M. PubMed
  • Drug Metab Dispos. 2019;47:768-778. A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters. Tátrai P, Schweigler P, Poller B, Domange N, de Wilde R, Hanna I, Gáborik Z, Huth F. PubMed
  • Eur J Pharm Sci. 2019;132:132-141. Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical models. Riede J, Umehara KI, Schweigler P, Huth F, Schiller H, Camenisch G, Poller B. PubMed
  • J Pharm Sci. 2017;106:2805-2814. Current in vitro methods to determine hepatic Kpuu: A comparison of their usefulness and limitations. Riede J, Camenisch G, Huwyler J, Poller B. PubMed
  • Drug Metab Dispos. 2017;45:523-531. Assessing the risk of drug-induced cholestasis using unbound intrahepatic concentrations. Riede J, Poller B, Huwyler J, Camenisch G. PubMed
  • Eur J Pharm Sci. 2016;86:96-102. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data. Riede J, Poller B, Umehara K, Huwyler J, Camenisch G. PubMed
  • Drug Metab Pers Ther. 2015;30:175-88. Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins. Kunze A, Poller B, Huwyler J, Camenisch G. PubMed
  • Drug Metab Dispos. 2014;42:1514-21. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Kunze A, Huwyler J, Camenisch G, Poller B. PubMed
  • J Pharm Sci. 2014;103:994-1001. In vitro-in vivo extrapolation method to predict human renal clearance of drugs. Kunze A, Huwyler J, Poller B, Gutmann H, Camenisch G. PubMed
  • Pharmacol Biochem Behav. 2012;102:312-20. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Schmitt U1, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, Gutmann H. PubMed
  • J Pharmacol Exp Ther. 2012;341:164-73. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH. PubMed
  • Int J Cancer. 2012;130:223-33. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH. PubMed
  • Mol Pharm. 2011;8:571-82. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Poller B, Wagenaar E, Tang SC, Schinkel AH. PubMed
  • Drug Metab Dispos. 2011;39:729-35. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. PubMed
  • Cell Mol Neurobiol. 2010;30:63-70. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H. PubMed
  • J Neurochem. 2008;107:1358-68. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J, Huwyler J. PubMed


Basel, Switzerland


Last update: April 2021